2,636 AbbVie Inc. $ABBV Shares Bought by Cooper Financial Group

Cooper Financial Group boosted its stake in AbbVie Inc. (NYSE:ABBV) by 23.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,096 shares of the company’s stock after acquiring an additional 2,636 shares during the period. Cooper Financial Group’s holdings in AbbVie were worth $3,687,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ABBV. Elm3 Financial Group LLC purchased a new stake in AbbVie in the third quarter worth $449,000. Canandaigua National Trust Co of Florida purchased a new position in AbbVie during the third quarter valued at $697,000. Bath Savings Trust Co boosted its holdings in shares of AbbVie by 7.0% during the 3rd quarter. Bath Savings Trust Co now owns 24,337 shares of the company’s stock valued at $6,366,000 after buying an additional 1,586 shares in the last quarter. Echo45 Advisors LLC purchased a new stake in shares of AbbVie in the 3rd quarter worth about $221,000. Finally, PFW Advisors LLC grew its position in shares of AbbVie by 5.4% in the 3rd quarter. PFW Advisors LLC now owns 917 shares of the company’s stock worth $240,000 after buying an additional 47 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations for AbbVie’s investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations could accelerate development and regulatory review for the antibody-drug conjugate, strengthening AbbVie’s growing oncology pipeline. Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
• Positive Sentiment: AbbVie and Genmab reported that the Epkinly (epcoritamab) plus R-CHOP combination reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 success supports potential expansion into frontline treatment and could improve the long-term commercial outlook for the partnership. AbbVie Cut Frontline DLBCL Progression Or Death Risk By 51%
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, adding to bullish analyst sentiment around the company’s pipeline and earnings potential. AbbVie Stock Price Target Raised at Scotiabank
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may remain focused on whether upcoming results and management commentary support the current premium valuation and forward growth expectations. Should You Buy AbbVie Stock Before Oct. 30?
• Negative Sentiment: AbbVie updated third-quarter 2026 EPS guidance to $3.73-$3.77, below the roughly $3.85 consensus estimate. The lower outlook may limit near-term upside and suggests investors will scrutinize operating performance despite the positive drug-development news. AbbVie Issues Q3 2026 Earnings Guidance
• Negative Sentiment: One report highlighted AbbVie’s payout ratio of about 190%, raising concerns that the dividend currently exceeds reported earnings and could face pressure if cash flow weakens. This is a longer-term risk rather than a direct change to the dividend policy. AbbVie Pays Out More Than It Earns

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

AbbVie Trading Up 1.8%

NYSE:ABBV traded up $4.67 during trading hours on Wednesday, reaching $271.37. The company had a trading volume of 6,075,433 shares, compared to its average volume of 6,434,720. The firm has a market cap of $479.44 billion, a price-to-earnings ratio of 76.66, a PEG ratio of 1.20 and a beta of 0.24. The firm’s 50 day moving average price is $258.27 and its 200-day moving average price is $235.87. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $274.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio is currently 195.48%.

Analyst Ratings Changes

ABBV has been the subject of a number of analyst reports. Morgan Stanley raised their target price on shares of AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. Guggenheim lifted their price target on AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $240.00 price target (down from $250.00) on shares of AbbVie in a research note on Wednesday, September 16th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Finally, Weiss Ratings raised shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $274.32.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.